^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-15R agonist

    Related drugs:
    Apply
    Study of NKTR 255 in Combination With Cetuximab in Solid Tumors (NCT04616196)
    Phase 1/2
    Nektar Therapeutics
    Completed
    Last update posted :
    05/13/2024
    Initiation :
    10/30/2020
    Primary completion :
    03/30/2023
    Completion :
    03/30/2023
    PD-L1 • CD4
    |
    MSI-H/dMMR
    |
    Erbitux (cetuximab) • avipendekin pegol (NKTR-255)
    CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies (NCT03233854)
    Phase 1
    Crystal Mackall, MD
    Active, not recruiting
    Last update posted :
    02/28/2024
    Initiation :
    09/01/2017
    Primary completion :
    09/01/2025
    Completion :
    09/01/2035
    CD19 • CD22
    |
    CD19 positive • CD19 expression • CD22 expression
    |
    cyclophosphamide • fludarabine IV • avipendekin pegol (NKTR-255) • cyclophosphamide intravenous
    NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma (NCI-2022-02316) (NCT05359211)
    Phase 1
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    02/06/2024
    Initiation :
    12/08/2022
    Primary completion :
    12/31/2024
    Completion :
    12/31/2025
    CD19
    |
    CD19 expression
    |
    cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • fludarabine IV • avipendekin pegol (NKTR-255)
    A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors (NCT03995472)
    Phase 1
    Jiangsu HengRui Medicine Co., Ltd.
    Completed
    Last update posted :
    09/27/2023
    Initiation :
    02/14/2020
    Primary completion :
    01/12/2023
    Completion :
    01/12/2023
    CD8
    |
    Ariely (adebrelimab) • SHR-1501